# Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

> **NCT00086983** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** becatecarin
- **DRUG:** oxaliplatin
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00086983
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2006-09
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086983, "Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00086983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*